Date: 11 Jan 2011
Therapeutic Update in Idiopathic Pulmonary Fibrosis
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Idiopathic pulmonary fibrosis (IPF) is a disease of the elderly with a mean age at presentation of 66 years. It is the most common type of idiopathic lung fibrosis, and the most lethal, with a median survival of 3 to 5 years after diagnosis. Abnormalities in fibroblast and humoral response mechanisms may play a role in the pathogenesis of fibrosis in IPF. Clinical trials suggest that pirfenidone, an oral antifibrotic agent, N-acetylcysteine, an antioxidant and perhaps anticoagulation, may have some beneficial effect; however, large-scale studies are necessary for confirmation. Immunosuppression with corticosteroids likely does not confer benefit. Lung transplantation has been shown to improve survival in selected IPF patients. Comorbidities accompanying IPF include gastroesophageal reflux, sleep disturbance, pulmonary arterial hypertension, and coronary artery disease amongst others, and ought to be promptly recognized and managed appropriately. While the US Food and Drug Administration has not currently approved any treatments for IPF, patients with IPF should continue to be strongly encouraged to enroll in ongoing clinical trials for this devastating disease.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias (2002) This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 165:277–304
American Thoracic Society (2000) Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161:646–664
Anonymous (2003) Interstitial lung disease. In: European lung white book: the first comprehensive survey on respiratory health in Europe. Loddenkemper R, Gibson G.J., Sibille, Y. (ed). European Respiratory Society, pp. 74–83
Selman M, King TE, Pardo A (2001) Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134:136–151PubMed
King TE Jr, Tooze JA, Schwarz MI, Brown KR, Cherniack RM (2001) Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med 164:1171–1181PubMed
National Cancer Institute (accessed Feb. 11, 2007). SEER Cancer Statistical Review 1975–2003. Acute myeloid leukemia. Available from: http://seer.cancer.gov/statfacts/html/amyl.html
Borchers AT, Chang C, Keen CL, Gershwin ME (2010) Idiopathic pulmonary fibrosis—an epidemiological and pathological review. Clin Rev Allergy Immunol (in press)
Richeldi L, Davies HR, Ferrara G, Franco F (2003) Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev, CD002880.
Davies HR, Richeldi L, Walters EH (2003) Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev, CD003134.
Park SH, Saleh D, Giaid A, Michel RP (1997) Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 156:600–608PubMed
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2010) A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 363:620–628CrossRef
American Heart Association (2003) Heart Disease and Stroke Statistics—2004 Update. Dallas, TX: American Heart Association, 6: 9–12.
- Therapeutic Update in Idiopathic Pulmonary Fibrosis
Clinical Reviews in Allergy & Immunology
Volume 44, Issue 1 , pp 65-74
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press Inc
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Division of Pulmonary, Critical Care and Sleep Medicine, UC Davis School of Medicine, 4150 V Street, Suite 3400, Sacramento, CA, USA
- 2. VA Northern California Health Care System, Mather, CA, USA